Yvette Soignier

Targeting Ewing Sarcoma By ROR1 CAR CXCR2 NK Cells Combined with CamB7-H3 Tri-Specific Killer Engager and Anti-GD2 Antibody

Wen Luo, Hongwen Zhu, Yvette Soignier, Martin Felices et autres

Introduction Patients diagnosed with metastatic Ewing sarcoma (ES) have a dismal outcome. Lines of evidence have shown the importance of NK cell immunity against ES [1]. However, NK cell number and function are low in ES patients, in large part due to …

us (code pays fourni par la source)

Dual-functioning Targeted ADAM17 Blocker CD16 (TAB16) mediates selective ADAM17 inhibition in NK cells and engages overexpressed ADAM17 in tumor cells to induce cytotoxicity

Kate J. Dixon, Robert Hullsiek, Sam C. Wang, Ryan R. Friess et autres

Introduction: Natural killer (NK) cells are innate lymphocytes that kill tumor cells by natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC). Human NK cells mediate the latter process exclusively by the IgG Fc receptor CD16 (FcγRIIIA). Cell surface levels of this activating receptor …

us (code pays fourni par la source)

Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy

W. Luo, Yvette Soignier, Shiori Eguchi, Janet Ayello et autres

Background & Aim Patients diagnosed with relapsed/refractory (R/R) Neuroblastoma (NB) and Sarcoma (SARC) have a dismal outcome. Lines of evidence have shown the importance of NK cell immunity against NB and SARC. However, NK cell number and function are low in NB …

us (code pays fourni par la source)

Abstract LB231: IGF1R targeted NK cell engager kills proliferating and quiescent hormone receptor positive breast cancers

Courtney Baar, Emily Chiu, Yvette Soignier, Jeffrey T. Miller et autres

Abstract Patients with hormone receptor-positive (HR+) breast cancers frequently recur with metastatic disease 5-20 years after initial diagnosis and completion of chemotherapy and prolonged hormonal therapy treatment. A potential mechanism of resistance in HR+ patients is the presence of slow dividing or …

1077 A novel dual-targeting engager strategy to amplify natural killer cell activity against ovarian cancer

Terran D Stenger, Joshua M. Walker, Yvette Soignier, Martin Felices et autres

Background Ovarian cancer (OC) is the 5th deadliest cancer among women and the most lethal gynecologic malignancy. Despite recent advancements in maintenance therapy, 70–80% of patients experience recurrence, with an average post-recurrence survival duration of under two years. Immunotherapy holds promise for …

us (code pays fourni par la source)

Tumor Microenvironment Spatial Analysis after Adoptive NK Cell Therapy for Lymphoma Revealed Cross-Talk with Adaptive T-Cell Immunity

Veronika Bachanová, Jeffrey S. Miller, Joseph E. Maakaron, Yvette Soignier et autres

126P Novel B7-H3 targeting dual nanobody NK cell engagers display robust activity against a broad spectrum of solid and hematologic malignancies

Nicholas A. Zorko, Martin Felices, Aimee Marie Merino, Joshua M. Walker et autres

us (code pays fourni par la source)

haploidentical NK cells in cancer patients Successful adoptive transfer and in vivo expansion of human

Arne Slungaard, Daniel Jordan Weisdorf, Ian J. Okazaki, David H. McKenna et autres

Abstract We previously demonstrated that autologous NK cell therapy after hematopoietic cell transplantion (HCT) is safe but does not provide an anti-tumor effect. We hypothesize that this is due to a lack of NK cell inhibitory receptor mismatching with autologous tumor cells …

us (code pays fourni par la source)

Oct3 and Sox2 Expression in Mammary Carcinoma Cells

Yvette Soignier

A complex transcriptional circuitry is essential in maintaining the self-renewal capacity and the undifferentiated state of embryonic stem cells (ESCs). Key factors in this pluripotency network include Sox2, Nanog, and Oct3/4, which form multiple positive and negative feedback loops to regulate an …

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Jeffrey S. Miller, Yvette Soignier, Angela Panoskaltsis‐Mortari, Sarah A. McNearney et autres

We previously demonstrated that autologous natural killer (NK)-cell therapy after hematopoietic cell transplantation (HCT) is safe but does not provide an antitumor effect. We hypothesize that this is due to a lack of NK-cell inhibitory receptor mismatching with autologous tumor cells, which …

us (code pays fourni par la source)

Successful Remission of Poor Prognosis AML after Adoptive Transfer and In Vivo Expansion of Human Haploidentical NK Cells.

Jeffrey S. Miller, Yvette Soignier, Angela Panosskaltsis-Mortari, David H. McKenna et autres

Abstract We previously demonstrated that although autologous NK cell therapy after hematopoietic cell transplantation (HCT) is safe, it does not provide an anti-tumor effect. We hypothesize that the lack of NK cell inhibitory receptor (KIR) mismatching with autologous tumor cells limits anti-tumor …

us, gb (code pays fourni par la source)

BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs)

Elena Gabriela Chiorean, Scott J. Dylla, Krista Olsen, Todd R. Lenvik et autres

Natural killer (NK) cells decrease in function during chronic myelogenous leukemia (CML) progression from chronic phase to blast crisis, and they can become BCR/ABL(+) late in the disease course. To study this altered function, NK92 cells were transduced with the BCR/ABL oncogene. …

us (code pays fourni par la source)